KR950700298A - 뉴클레오시드 치료제(Therapeutic Nucleosides) - Google Patents

뉴클레오시드 치료제(Therapeutic Nucleosides)

Info

Publication number
KR950700298A
KR950700298A KR1019940702965A KR19940702965A KR950700298A KR 950700298 A KR950700298 A KR 950700298A KR 1019940702965 A KR1019940702965 A KR 1019940702965A KR 19940702965 A KR19940702965 A KR 19940702965A KR 950700298 A KR950700298 A KR 950700298A
Authority
KR
South Korea
Prior art keywords
therapeutic nucleosides
nucleosides
therapeutic
preparation
relates
Prior art date
Application number
KR1019940702965A
Other languages
English (en)
Other versions
KR100282584B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950700298A publication Critical patent/KR950700298A/ko
Application granted granted Critical
Publication of KR100282584B1 publication Critical patent/KR100282584B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1019940702965A 1992-02-25 1993-02-24 뉴클레오시드 치료제 KR100282584B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929204015A GB9204015D0 (en) 1992-02-25 1992-02-25 Therapeutic nucleosides
GB9204015.3 1992-02-25
PCT/GB1993/000378 WO1993017020A2 (en) 1992-02-25 1993-02-24 Therapeutic nucleosides

Publications (2)

Publication Number Publication Date
KR950700298A true KR950700298A (ko) 1995-01-16
KR100282584B1 KR100282584B1 (ko) 2001-02-15

Family

ID=10711016

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702965A KR100282584B1 (ko) 1992-02-25 1993-02-24 뉴클레오시드 치료제

Country Status (14)

Country Link
US (5) US5641889A (ko)
EP (1) EP0628044B1 (ko)
JP (1) JP3172533B2 (ko)
KR (1) KR100282584B1 (ko)
AT (1) ATE245646T1 (ko)
AU (2) AU3571093A (ko)
CA (1) CA2130755C (ko)
DE (1) DE69333109T2 (ko)
DK (1) DK0628044T3 (ko)
ES (1) ES2203615T3 (ko)
GB (1) GB9204015D0 (ko)
HK (1) HK1003941A1 (ko)
PT (1) PT628044E (ko)
WO (1) WO1993017020A2 (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631370A (en) * 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
DE69431596D1 (de) * 1993-06-10 2002-11-28 Wake Forest University Winston (phospho)lipide zum bekämpfen einer hepatitis b-infektion
JP3479077B2 (ja) 1993-06-21 2003-12-15 メレルファーマス−ティカルズ インコーポレイテッド プロ炎症性サイトカインの選択的抑制剤として有用な新規な炭素環式ヌクレオシド剤
EP0630897A3 (en) * 1993-06-25 1995-03-01 Bristol Myers Squibb Co 3-hydroxy-4-hydroxymethyl-2-methylene-cyclopentyl purines and pyrimidines.
WO1995022330A1 (en) * 1994-02-17 1995-08-24 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
US5962437A (en) 1994-08-29 1999-10-05 Wake Forest University Lipid analogs for treating viral infections
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
IL127235A (en) 1996-05-30 2003-04-10 Lonza Ag Process for the preparation of amino alcohols and derivatives thereof
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
SK284810B6 (sk) * 1997-05-13 2005-12-01 Lonza Ag Spôsob výroby (1S,4R)- alebo (1R,4S)-4-(2-amino-6-chlór-9-H- purín-9-yl)-2-cyklopentén-1-metanolu
CZ298102B6 (cs) * 1997-11-27 2007-06-20 Lonza Ag Zpusob výroby aminoalkoholu
US6362225B1 (en) * 1999-01-21 2002-03-26 George Andreakos Target therapies for treating common viral infections
US6514979B1 (en) 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
WO2001018003A1 (en) * 1999-09-10 2001-03-15 Stichting Rega Vzw Carbocyclic nucleosides and process for obtaining such
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
EP1334969A4 (en) * 2000-10-18 2005-08-24 Kuraray Co PREPARATION OF 4-N SUBSTITUTED AMINO-2-AZA-1-OXYBICYCLO 3.3.0] OCT-2-ENE-6-CARBOXYLIC ACID ESTERS AND PREPARATION OF THEIR INTERMEDIATE PRODUCTS
JP4381804B2 (ja) 2001-06-27 2009-12-09 サイクラセル リミテッド ２，６，９−置換プリン誘導体及び増殖性疾患の治療におけるその使用
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
CA2463719A1 (en) 2003-04-05 2004-10-05 F. Hoffmann-La Roche Ag Nucleotide analogs with six membered rings
GB0320738D0 (en) * 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
WO2005075426A1 (en) * 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7230002B2 (en) 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
US7767686B2 (en) * 2006-03-03 2010-08-03 Covidien Ag Method of using adenosine receptor blockers during tissue ablation
US20070208042A1 (en) * 2006-03-03 2007-09-06 Sherwood Services Ag Method of using vasoconstrictive agents during energy-based tissue therapy
CN103483342B (zh) 2007-08-02 2016-08-31 米伦纽姆医药公司 合成e1活化酶抑制剂的方法
AR072937A1 (es) * 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituida y su uso en el tratamiento de infecciones virales
AR072940A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
TW201019939A (en) * 2008-08-20 2010-06-01 Schering Corp Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282574B2 (en) 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US20120295898A1 (en) 2010-01-27 2012-11-22 Mark Richard Underwood Antiviral Therapy
WO2012139230A1 (en) 2011-04-14 2012-10-18 Phonak Ag Hearing instrument
GB201513601D0 (en) * 2015-07-31 2015-09-16 Univ Liverpool Antiviral compounds
CN106220515A (zh) * 2016-08-12 2016-12-14 郸城巨鑫生物科技有限公司 一种(1r,4s)‑1‑氨基‑4‑羟甲基‑2‑环戊烯盐酸盐的合成方法
WO2018181102A1 (ja) * 2017-03-29 2018-10-04 ヤマサ醤油株式会社 ヌクレオシド誘導体又はその塩、及びそれを含む医薬組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60139653A (ja) * 1983-12-27 1985-07-24 Yoshitomi Pharmaceut Ind Ltd シクロペンテン誘導体
US4543255A (en) * 1984-05-10 1985-09-24 Southern Research Institute Carbocyclic analogs of purine 2'-deoxyribofuranosides
EP0219838A3 (en) * 1985-10-22 1988-04-06 Takeda Chemical Industries, Ltd. Carbocyclic purine nucleosides, their production and use
IN164556B (ko) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4734194A (en) * 1986-03-25 1988-03-29 The Upjohn Company Combined filter and valve mechanism
IN166499B (ko) * 1987-02-12 1990-05-19 Takeda Chemical Industries Ltd
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
WO1990006671A2 (en) * 1988-12-12 1990-06-28 Palese Peter M Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
ES2067693T3 (es) * 1989-10-16 1995-04-01 Chiroscience Ltd Azabicicloheptanona quiral y un procedimiento para su preparacion.
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
CA2053849A1 (en) * 1990-03-06 1991-09-07 David I. Scheer Methods and compositions for the prophylaxis and treatment of cytomegalovirus infections
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides

Also Published As

Publication number Publication date
EP0628044B1 (en) 2003-07-23
AU2489197A (en) 1997-08-28
AU3571093A (en) 1993-09-13
WO1993017020A3 (en) 1994-03-17
GB9204015D0 (en) 1992-04-08
US5808147A (en) 1998-09-15
KR100282584B1 (ko) 2001-02-15
WO1993017020A2 (en) 1993-09-02
AU707075B2 (en) 1999-07-01
DE69333109T2 (de) 2004-04-15
US5840990A (en) 1998-11-24
US5641889A (en) 1997-06-24
PT628044E (pt) 2003-12-31
JPH07504185A (ja) 1995-05-11
CA2130755A1 (en) 1993-08-26
US6392085B2 (en) 2002-05-21
DK0628044T3 (da) 2003-11-17
ES2203615T3 (es) 2004-04-16
HK1003941A1 (en) 1998-11-13
CA2130755C (en) 2004-03-30
ATE245646T1 (de) 2003-08-15
DE69333109D1 (de) 2003-08-28
US20010008946A1 (en) 2001-07-19
EP0628044A1 (en) 1994-12-14
JP3172533B2 (ja) 2001-06-04
US5919941A (en) 1999-07-06

Similar Documents

Publication Publication Date Title
KR950700298A (ko) 뉴클레오시드 치료제(Therapeutic Nucleosides)
BR9305907A (pt) Uso de derivados de substituída para tratamento de esclerose múltipla
FI913236A (fi) 9-purinylfosfonsyraderivat.
ATE179983T1 (de) Antiretrovirale, enantiomere nukleotid-analoge
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
AU8110991A (en) Novel carbocyclic analogs of certain nucleosides
ES2149157T3 (es) Nuevo procedimiento para la preparacion de nucleotidos.
FI932997A0 (fi) Antivirala foereningar
ES2132419T3 (es) Nuevos agentes de nucleosidos 9-n-biciclicos utiles como inhibidores selectivos de citocinas proinflamatorias.
MX9305093A (es) Nuevos derivadosindano-2 mercaptoacetilamina triciclicos 2-sustituidos, utiles como inhibidores de la encefalinasa.
SE9604582D0 (sv) Novel compounds
IT8721560A0 (it) Procedimento per la purificazione di interferone.
ES2133573T3 (es) Analogos antiviricos de difluoro estatone.
NO974512L (no) Fremgangsmåte for syntese av nukleosid-analoger
SE9603726D0 (sv) Novel compounds
AR240397A1 (es) Banera para aplicacion de hidromasajes por burbujeo.
SU1279221A1 (ru) 3-Метил-1-(4-тиоцианатофенил)-5-(2-фурил-)-Δ-пиразолин, проявляющий противовоспалительную активность

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121030

Year of fee payment: 13

EXPY Expiration of term